A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as hormone therapy. This study is for individuals who have been diagnosed with advanced, high-risk prostate cancer and standard therapies available to treat your disease have not been effective. Participation in this research will last about 3 years and 9 months.

Trial Details

NCT ID
NCT05726292
Phase
PHASE2
Sponsor
University of Chicago
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Relacorilant
  • Enzalutamide
  • Placebo (Sugar Pill)
  • Androgen Deprivation Therapy
  • Radical Prostatectomy
Locations (sample)
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Evanston, Illinois, United States|42.04114,-87.69006
  • Portland, Oregon, United States|45.52345,-122.67621
  • Dallas, Texas, United States|32.78306,-96.80667

Key Eligibility Criteria

  • Histologically or cytologically confirmed prostatic adenocarcinoma without primary small cell histology
  • Localized disease:
  • Surgical resectability must be documented prior to enrollment
  • No evidence of distant metastatic disease on abdominopelvic imaging, bone imaging

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →